tisotumab vedotin
seagen,genmab
['gyn']
the combination of tisotumab vedotin (#adc to tissue factor) and carboplatin in frontline #cervicalcancer 55% response rate, 91% clinical benefit!!! #asco22 #gyncsm 
Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. #JCO social media editor. Opinions=mine.
https://t.co/QLXLDKSThc